Donepezil, an acetylcholinesterase (AChE) inhibitor, was approved by FDA for the symptomatic therapies of patients with Alzheimer’s disease (AD) in 1996. Although donepezil have been regarded as the standard and first-line treatment for AD, the capacity of such drugs to alter the underlying disease ...
This study is designed to investigate the protective function of cholinesterase inhibitor Donepezil (DON) in regulating Group III pulmonary hypertension (PH).
